Background/Aims: We planned to report on the effect of two nonanimal chondroitin sulfates (CSs) with different molecular masses produced using an innovative biotechnological process in an adjuvant arthritis animal model. Methods: The experiments included healthy animals, untreated arthritic animals and arthritic animals having been administered 900 mg/kg of either of the two CS samples daily. Arthritic score, γ-glutamyltransferase (GGT) activity in hind paw joint tissue homogenates, plasmatic C-reactive protein (CRP) and pro-inflammatory cytokines IL-1β and IL-6 were assayed. Results and Conclusions: Low-molecular-mass (LMM) CS significantly reduced the arthritic score by up to about 30% from 14 to 28 days. In contrast, no significant differences were observed for high-molecular-mass (HMM) CS, even if a trend in its capacity to decrease the arthritic score by up to about 11% was observed. Additionally, LMM CS was able to significantly decrease GGT activity by approximately 31% and plasmatic CRP levels by about 9%. Both nonanimal CS samples were effective in reducing plasmatic levels of proinflammatory cytokines. A greater efficacy was also observed for LMM CS compared with a pharmaceutical-grade CS of extractive origin, while the efficacy of the HMM CS sample was found to be rather similar. The greater effect of LMM CS in reducing arthritic parameters may be related to its lower molecular mass with respect to HMM CS and natural CS.

Keywords:
Adjuvant arthritis, Chondroitin sulfate, Biotechnological process, Glycosaminoglycans, Osteoarthritis, Rheumatoid arthritis
1.
Uebelhart D: Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008;16:S19-S21.
2.
Jordan KM, et al: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155.
3.
Zhang W, et al: EULAR evidence based recommendations for the management of hand osteoarthritis. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-388.
4.
McAlindon TE, et al: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-1475.
5.
Volpi N, Maccari F: Quantitative and qualitative evaluation of chondroitin sulfate in dietary supplements. Food Anal Methods 2008;1:195-204.
6.
Reginster JY, et al: Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Rev Med Chem 2007;7:1051-1061.
7.
Kahan A, et al: Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-533.
8.
Volpi N: Chondroitin Sulfate: Structure, Role and Pharmacological Activity. Amsterdam, Academic Press, 2006.
9.
Volpi N: Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 2007;96:3168-3180.
10.
Volpi N: Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 2009;61:1271-1280.
11.
Casu B, et al: Chemical derivatization as a strategy to study structure-activity relationships of glycosaminoglycans. Semin Thromb Hemost 2002;28:335-342.
12.
Karst NA, Linhardt RJ: Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides. Curr Med Chem 2003;10:1993-2031.
13.
Jacquinet JC, et al: From polymer to size-defined oligomers: a highly divergent and stereocontrolled construction of chondroitin sulfate A, C, D, E, K, L, and M oligomers from a single precursor. Part 2. Chemistry 2009;15:9579-9595.
14.
Bedini E, et al: A microbiological-chemical strategy to produce chondroitin sulfate A, C. Angew Chem Int Ed Engl 2011;50:6160-6163.
15.
Herrero-Beaumont G, et al: Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol 2008;154:843-851.
16.
Kannan K, et al: Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12:167-181.
17.
Bauerova K, et al: Chondroitin sulfate effect on induced arthritis in rats. Osteoarthritis Cartilage 2011;19:1373-1379.
18.
Biotechnological production of chondroitin. Patent No PCT/EP2011/059069 - WO 2012004063 A1.
19.
Shark-like chondroitin sulphate and process for the preparation thereof. Patent No PCT/EP2011/058297 - WO 2012159655 A1.
20.
Low-molecular-weight biotechnological chon- droitin 6-sulphate for prevention of osteoarthritis. Patent No PCT/EP2013/060471 - WO 2013174847 A1.
21.
Tat SK, et al: Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process. J Rheumatol 2010;37:656-664.
22.
Barnhill JG, et al: Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. J Am Pharm Assoc (2003) 2006;46:14-24.
23.
Malavaki CJ, et al: Capillary electrophoresis for the quality control of chondroitin sulfates in raw materials and formulations. Anal Biochem 2008;374:213-220.
24.
Møller HJ, et al: Demonstration of immunogenic keratan sulphate in commercial chondroitin 6-sulphate from shark cartilage. Implications for ELISA assays. Clin Chim Acta 1995;236:195-204.
25.
Pomin VH, et al: Residual keratan sulfate in chondroitin sulfate formulations for oral administration. Carbohydr Polym 2012;90:839-846.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.